NCT04217356View on ClinicalTrials.gov

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

RecruitingOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

August 5, 2025

Study Completion Date

February 5, 2026

Conditions
MyelofibrosisHigh-Risk CancerBone Marrow Cancer
Interventions
BIOLOGICAL

Hematopoietic stem cell transplant

Intravenous infusion of hematopoietic stem cells from a donor.

DRUG

Ruxolitinib

Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).

DRUG

Hydroxyurea

Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).

Trial Locations (5)

T2N4N2

RECRUITING

Tom Baker Cancer Centre, Calgary

T6G2G3

NOT_YET_RECRUITING

Cross Cancer Institute, Edmonton

V6E1M7

NOT_YET_RECRUITING

St. Paul's Hospital, Vancouver

B3H2Y9

NOT_YET_RECRUITING

Nova Scotia Health Authority, Halifax

M5G2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER